Lexaria Bioscience Corp. announced on December 9, 2024, the engagement of a contract research organization (CRO) to design and execute a human pilot study. This study will evaluate DehydraTECH-liraglutide against Saxenda® injectable liraglutide.
The decision to advance liraglutide into human trials follows positive results from a 12-week rodent study reported on November 20, 2024. In that study, oral DehydraTECH-processed liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar reduction compared to baseline.
This new human study represents a strategic expansion of Lexaria's GLP-1 pipeline, aiming to demonstrate the potential of its DehydraTECH technology to create an oral alternative for another widely used injectable GLP-1 drug.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.